What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce Abbott Laboratories' financial results for the first quarter of 2024 and to incorporate the related press release into the official record.

What are non-GAAP financial measures and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from standard GAAP (Generally Accepted Accounting Principles) accounting. Abbott uses them to provide investors with a clearer understanding of the company's ongoing operational performance by excluding items that management considers unusual or unpredictable, such as acquisition-related costs, restructuring charges, and amortization of intangibles.

What are some examples of items excluded from Abbott's non-GAAP measures?

Abbott excludes items such as expenses related to acquisitions, restructuring actions, cost reduction initiatives, fair value adjustments to contingent consideration, impairment charges, certain regulatory and tax costs, and intangible amortization expense.

How should investors interpret Abbott's use of non-GAAP measures?

Abbott's management believes these non-GAAP measures provide useful information for evaluating ongoing business performance. However, the company cautions investors to consider these non-GAAP measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) has filed an 8-K report on April 17, 2024, to announce its first-quarter 2024 financial results. The filing primarily incorporates a press release detailing these results and highlights the use of non-GAAP financial measures. These non-GAAP measures exclude items such as acquisition-related expenses, restructuring costs, fair value adjustments, impairment charges, certain regulatory and tax items, and intangible amortization. Management utilizes these non-GAAP figures to offer investors a clearer view of ongoing operational performance, as they believe these adjustments provide better insight into the core business's results, aligning with internal performance assessments. While Abbott emphasizes the utility of these non-GAAP measures for evaluating business performance, it also strongly advises investors to consider them alongside, and not as a replacement for, standard GAAP financial metrics.

Key Highlights

1Abbott Laboratories reported its first-quarter 2024 financial results on April 17, 2024, via an 8-K filing.
2The report incorporates a press release announcing the Q1 2024 financial performance.
3The company prominently uses non-GAAP financial measures in its reporting.
4These non-GAAP measures exclude various unusual or unpredictable items, including acquisition and restructuring costs.
5Management believes non-GAAP measures offer enhanced visibility into ongoing business performance.
6Abbott recommends investors use non-GAAP measures in conjunction with, not as a substitute for, GAAP measures.

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 17, 2024)

Summary

Key Highlights

Frequently Asked Questions